Leqvio (Inclisiran) Dosing & Administration (Instructions for Use)
Dosing Regimen, Administration and Instructions for Use
Semaglutide (Ozempic) Instructions for Use
Indications: 1) Diabetes 2) Weight Loss
Mounjaro (Tirzepatide) Instructions for Use
Mounjaro (Tirzepatide) Indications: Diabetes & Weight Loss Instructions for Use
Vtama (tapinarof) 1% Topical Cream (60 gram)
Vtama (tapinarof) 1% Topical Cream for the Treatment of Plaque Psoriasis is Available
Saxenda (Liraglutide), Wegovy (Semaglutide) and Mounjaro (Tirzepatide) SC Injections for Type 2 Diabetes and Weight Management
Drug Info: ApoThera Drug Disease Clinical Support App Diabetes Mellitus, Type 2 Initial Dose – 2.5 mg SC every week x 4 weeks Maintenance Dose – Increase to 5 mg…
FDA Approves Lilly and Incyte’s OLUMIANT (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib), a once-daily pill, as a first-in-disease systemic treatment…
Risankizumab (SKYRIZI) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn’s Disease in Adults
Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely active Crohn's disease,…
FDA Approves Fylnetra (pegfilgrastim-pbbk), Biosimilar to Neulasta (pegfilgrastim), for Treating Neutropenia
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a…
FDA Approves Dermavant’s VTAMA (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in Adults
FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years EFFICACY: In…
Priorix becomes an additional source of measles, mumps and rubella vaccine for US patients
GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older GSK plc (LSE/NYSE: GSK) today announced that…